Latest Information Update: 12 Apr 2010
At a glance
- Originator Sucampo Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 14 Nov 2005 No development reported - Phase-II for Glaucoma in USA (Ophthalmic)
- 01 Oct 2003 Phase-II clinical trials in Glaucoma in USA (Ophthalmic)